Overall and progression-free survival of CML and Ph+ ALL patients from TKI resistance or T315I detection
| . | CML CP . | CML AP . | CML BP . | Ph+ ALL . |
|---|---|---|---|---|
| Survival since first time of TKI resistance, by phase at time of TKI resistance | ||||
| No. of patients | 88 | 34 | 54 | 46 |
| Median follow-up, mo | 27.7 | 19.8 | 6.2 | 4.8 |
| Median OS, mo (95% CI) | 51.4 (44.4-59.5) | 49.4 (15.2-52.0) | 8.3 (4.6-11.3) | 6.3 (5.0-12.2) |
| 1-y OS rate (95% CI) | 93% (85%-97%) | 72% (54%-85%) | 35% (22%-48%) | 37% (22%-53%) |
| Median PFS, mo (95% CI) | 17.2 (12.9-27.1) | 10.8 (5.3-34.0) | 3.6 (2.3-5.4) | 4.6 (2.3-5.2) |
| 1-y PFS rate (95% CI) | 66% (55%-75%) | 48% (30%-64%) | 19% (9%-30%) | 18% (7%-32%) |
| Survival since T315I mutation detection, by phase at T315I mutation detection | ||||
| No. of patients | 82 | 38 | 56 | 46 |
| Median follow-up, mo | 12.4 | 15.2 | 3.0 | 3.6 |
| Median OS, mo (95% CI) | 22.4 (18.2-48.5) | 28.4 (15.9-49.8) | 4.0 (2.0-5.0) | 4.9 (3.4-7.3) |
| 1-y OS rate (95% CI) | 71% (58%-80%) | 69 (50%-81%) | 23% (13%-36%) | 12% (3%-27%) |
| Median PFS, mo (95% CI) | 11.5 (9.2-15.7) | 22.2 (9.0-N/A) | 1.8 (1.2-4.0) | 2.5 (1.8-3.6) |
| 1-y PFS rate (95% CI) | 46% (34%-57%) | 56% (38%-70%) | 16% (7%-27%) | 7% (1%-19%) |
| . | CML CP . | CML AP . | CML BP . | Ph+ ALL . |
|---|---|---|---|---|
| Survival since first time of TKI resistance, by phase at time of TKI resistance | ||||
| No. of patients | 88 | 34 | 54 | 46 |
| Median follow-up, mo | 27.7 | 19.8 | 6.2 | 4.8 |
| Median OS, mo (95% CI) | 51.4 (44.4-59.5) | 49.4 (15.2-52.0) | 8.3 (4.6-11.3) | 6.3 (5.0-12.2) |
| 1-y OS rate (95% CI) | 93% (85%-97%) | 72% (54%-85%) | 35% (22%-48%) | 37% (22%-53%) |
| Median PFS, mo (95% CI) | 17.2 (12.9-27.1) | 10.8 (5.3-34.0) | 3.6 (2.3-5.4) | 4.6 (2.3-5.2) |
| 1-y PFS rate (95% CI) | 66% (55%-75%) | 48% (30%-64%) | 19% (9%-30%) | 18% (7%-32%) |
| Survival since T315I mutation detection, by phase at T315I mutation detection | ||||
| No. of patients | 82 | 38 | 56 | 46 |
| Median follow-up, mo | 12.4 | 15.2 | 3.0 | 3.6 |
| Median OS, mo (95% CI) | 22.4 (18.2-48.5) | 28.4 (15.9-49.8) | 4.0 (2.0-5.0) | 4.9 (3.4-7.3) |
| 1-y OS rate (95% CI) | 71% (58%-80%) | 69 (50%-81%) | 23% (13%-36%) | 12% (3%-27%) |
| Median PFS, mo (95% CI) | 11.5 (9.2-15.7) | 22.2 (9.0-N/A) | 1.8 (1.2-4.0) | 2.5 (1.8-3.6) |
| 1-y PFS rate (95% CI) | 46% (34%-57%) | 56% (38%-70%) | 16% (7%-27%) | 7% (1%-19%) |
Median survival and survival rates were calculated according to Kaplan-Meier method.